[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100548541":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":24,"centralContacts":28,"locations":36,"responsibleParty":71,"collaborators":18,"id":73,"slug":74,"hasResults":75,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":18,"eligibilityCriteria":79,"healthyVolunteers":75,"sex":80,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":18,"studyType":86,"phases":87,"briefSummary":89,"conditions":90,"keywords":94,"overallStatus":39,"whyStopped":18,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":109},{"fullName":5,"class":6},"Barcelona Institute for Global Health","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"IMCI-enhanced by suPAR levels (SoC + suPAR POC).","EXPERIMENTAL","IMCI-guidelines (standard of care) + Point-Of-Care (POC) test based on suPAR quantification",[13],"Other: IMCI-enhanced by suPAR levels (SoC + suPAR POC)",{"label":15,"type":16,"description":17,"interventionNames":18},"IMCI alone","NO_INTERVENTION","IMCI-guidelines (standard of care)",null,[20],{"type":6,"name":21,"description":22,"armGroupLabels":23,"otherNames":18},"IMCI-enhanced by suPAR levels (SoC + suPAR POC)","IMCI-guidelines (standard of care) + Point-Of-Care (POC) based on suPAR quantification",[9],[25],{"name":26,"affiliation":5,"role":27},"Quique Bassat, Prof","PRINCIPAL_INVESTIGATOR",[29,33],{"name":26,"role":30,"phone":31,"phoneExt":18,"email":32},"CONTACT","93 227 92 12","quique.bassat@isglobal.org",{"name":34,"role":30,"phone":31,"phoneExt":18,"email":35},"Barbara Baro, PhD","Barbara.baro@isglobal.org",[37,56],{"facility":38,"status":39,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"CERMEL Centre de Recherches Médicales de Lambaréné","RECRUITING","Lambaréné","Moyen-Ogooué Province","242","Gabon","GA",{"type":46,"coordinates":47},"Point",[48,49],10.24055,-0.7001,{"lat":49,"lon":48},[52],{"name":53,"role":30,"phone":54,"phoneExt":18,"email":55},"Selidji T. Agnandji","00241 07-98-91-91","agnandjis@cermel.org",{"facility":57,"status":39,"city":58,"state":18,"zip":18,"country":59,"countryCode":60,"cosmosGeoPoint":61,"geoPoint":65,"contacts":66},"Mopeia Sede Health Centre","Mopeia","Mozambique","MZ",{"type":46,"coordinates":62},[63,64],35.70333,-17.97722,{"lat":64,"lon":63},[67],{"name":68,"role":30,"phone":69,"phoneExt":18,"email":70},"Inácio Mandomando","+258-8243877418","inacio.mandomando@manhica.net",{"type":72,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR","100548541","a-rapid-triage-test-to-improve-risk-stratification-of-febrile-children-echilibrist-clinical-trial-1-outpatients-100548541",false,"NCT06422338","A Rapid Triage Test to Improve Risk-stratification of Febrile Children (EChiLiBRiST, Clinical Trial 1, Outpatients)","A Multi-country, Two-arm, Open-label, Superiority, Randomised Controlled Trial to Study the Performance of a Rapid Triage Test Compared to Standard of Care (IMCI-based) to Guide Admission\u002FDischarge Decisions During the First Clinical Assessment of Children With Fever","Inclusion Criteria:\n\n* Age ≥2 months and \\\u003C60 months\n* Written informed consent from the child's parent or caregiver\n* History of fever for ≤7 days OR hypothermia (i.e., axillary temperature \\\u003C35.5ºC) OR suspected severe infection (e.g., in children with moderate or severe acute malnutrition).\n* Lives within the catchment area of the study facility and must intend to continue to reside there for the duration of the study\n* For the RTI sub-study only: presence of respiratory symptoms compatible with RTI.\n\nExclusion Criteria:\n\n* Weight less than 2.5kg\n* Main reason for consultation is an injury, trauma or acute poisoning\n* Enrolled in another clinical trial testing a new drug\n* Enrolled in a vaccine trial in the last 3 months.\n* Any other condition determined by the investigators that makes it unlikely that the participant would complete the study","ALL","2 Months","60 Months",{"count":84,"type":85},5212,"ESTIMATED","INTERVENTIONAL",[88],"NA","The overall aim of the study is to provide evidence that introducing novel biomarkers evaluation at triaging (first clinical assessment), in combination with IMCI-based guidelines (SoC), is a viable strategy to enhance rapid and accurate identification of febrile children at increased risk of life-threatening infections compared to IMCI-based strategies alone (SoC), and to demonstrate whether this results in enhanced decisions of admission\u002Freferral vs discharge, and enhanced overall health outcome of children with acute fever in sub-Saharan Africa.",[91,92,93],"Infectious Disease","Febrile Illness","Child, Only",[95,96,97,98,99],"biomarkers","severity","point-of-care","triage","sub-Saharan Africa","2026-02-12",{"date":102,"type":103},"2026-02-17","ACTUAL",{"date":105,"type":103},"2025-07-02",{"date":107,"type":85},"2027-03-01",{"name":5,"class":6},2]